Sugi Predict

Sugi Predict / Compounds / SCHEMBL1041682

SCHEMBL1041682

SCHEMBL1041682

COc1ccc(Br)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 4/20 0.43
▸ AR P10275 3/20 0.42
▸ PGR P06401 2/20 0.42
▸ NOTUM Q6P988 2/20 0.41
▸ CYP11B1 P15538 1/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CA12 O43570 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA7 P43166 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ CA14 Q9ULX7 2/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451893 1.00 EPHX2 (0.43) EPHX2ARPGRNOTUMCYP11B1
SCHEMBL1042195 0.86 NOTUM (0.54) EPHX2ARPGRNOTUMCYP11B1
SCHEMBL9133188 0.82 CA1 (0.50) MAPTLMNACA12CA1CA2
SCHEMBL23457095 0.82 CA1 (0.41) MAPTCA12CA1CA2CA7
SCHEMBL4628852 0.81 EPHX2 (0.46) EPHX2ARPGRCYP11B1CYP11B2
SCHEMBL1045536 0.80 NOTUM (0.39) NOTUMMAPTLMNASMN1; SMN2EPHX1
SCHEMBL4059164 0.80 NOTUM (0.39) NOTUMMAPTLMNASMN1; SMN2EPHX1
SCHEMBL30649163 0.79 NQO1 (0.45) ARMAPTLMNAMEN1NPC1
SCHEMBL30628299 0.79 MAPT (0.42) NOTUMMAPTLMNASMN1; SMN2EPHX1
SCHEMBL3108999 0.79 NQO1 (0.45) ARMAPTLMNAMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-3135943-A — — None — — JP disclosed
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 — — US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 — — US disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP disclosed
WO-2024140968-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR 广州市联瑞制药有限公司 2024-07-04 — — WO disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
CN-111170991-B Antiproliferative compounds and methods of synthesis thereof 细胞基因公司 2023-10-31 — — CN disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
EP-0594257-B1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC (US) 1996-07-10 — — EP disclosed
US-5512589-A TREATING DEGENERATIVE DISEASES STERLING WINTHROP INC. (US) 1996-04-30 — — US disclosed
EP-0423991-B1 Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid SHOWA SHELL SEKIYU (JP) 1995-06-14 — — EP disclosed
EP-0594257-A1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC. (US) 1994-04-27 — — EP disclosed
US-5306818-A Treating degenerative diseases such as emphysema, rheumatoid arthritis and pancreatitis STERLING WINTHROP INC. (US) 1994-04-26 — — US disclosed
US-5183934-A 2-trifluoromethyl-4-hydroxybenzoic acid SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) 1993-02-02 — — US disclosed
JP-H03135943-A 2-TRIFLUOROMETHYL-4-HYDROXYBENZOIC ACID SHOWA SHELL SEKIYU KK 1991-06-10 — — JP disclosed
EP-0423991-A2 Process for the preparation of 2-trifluoromethyl-4-hydroxybenzoic acid Showa Shell Sekiyu Kabushiki Kaisha (JP) 1991-04-24 — — EP disclosed
EP-0193055-B1 ANTITUMORALS(1,2-DIPHENYL-ETHYLENE DIAMINE)-PLATINUM (II) COMPLEXES ASTA Pharma AG (DE) 1990-05-16 — — EP disclosed
US-4730068-A SPECIAL EFFECT ON BREAST CANCER ASTA-WERKE AKTIENGESELLSCHAFT (DE) 1988-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 EPHX2 1591/4885AR 4756/4885PGR 3293/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 EPHX2 1591/4885AR 4756/4885PGR 3293/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH EPHX2 3003/4885AR 4542/4885PGR 3666/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP EPHX2 2160/4885AR 1175/4885PGR 2203/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 EPHX2 1637/4885AR 3713/4885PGR 2997/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP EPHX2 2134/4885AR 1147/4885PGR 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.